PanOptica

About PanOptica

PanOptica, Inc. is a private, clinical-stage biopharmaceutical company dedicated to developing innovative treatments for neovascular eye diseases, which are conditions caused by abnormal or leaky blood vessels in the eye. The company's flagship product, PAN-90806, is a novel, topically applied, once-daily eye drop designed to treat sight-threatening conditions such as neovascular age-related macular degeneration (wet AMD) and diabetic retinopathy. These diseases are leading causes of blindness in the Western world.

PanOptica operates within the biopharmaceutical market, focusing on patients suffering from severe eye conditions. The company's business model revolves around the development and clinical testing of PAN-90806, supported by extensive preclinical research and clinical trials. PanOptica generates revenue through the development and potential future commercialization of its eye drop treatment, which offers a non-invasive alternative to current therapies that require injections.

PAN-90806 works by blocking VEGF (vascular endothelial growth factor) signaling at the receptor level, a proven mechanism for treating neovascular eye diseases. This approach differentiates it from existing treatments that bind VEGF directly. The eye drop has shown promising results in both preclinical and clinical trials, achieving significant and sustained levels in the retina and choroid, and effectively suppressing abnormal blood vessel formation.